Part 6/10:
The device is currently undergoing clinical trials in Europe, with the hope of being available in markets by 2026. For Hodak, this work is significantly personal, as he watched his grandfather navigate life with retinitis pigmentosa. The implications of the device are not only crucial for patients but hold considerable commercial potential, with projections estimating the product could generate billions in revenue, fueling further advances in neurotech.